InvestorsHub Logo
Followers 104
Posts 16740
Boards Moderated 3
Alias Born 12/07/2005

Re: None

Friday, 04/21/2017 4:35:50 AM

Friday, April 21, 2017 4:35:50 AM

Post# of 4859
Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread http://www.businesswire.com/news/home/20170420005335/en/Gilead-Presents-Data-International-Liver-Congress%E2%84%A2-2017/?feedref=JjAwJuNHiystnCoBq_hl-fqXyBvmekC3Xq1G1wQ7hjMFbZM1ntlKeK-8bUzJqFSVSfe41V1BKA-b6v2ZVrSSNs-dUYKiDvY7XniNSqv88QcY1Ge_vf9QIMZ4alzIf_0HlyE0C4hZhHVlTvKnn0d0vQ==
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News